Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com

NEW YORK, May 22, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.

Biogen Idec Inc. Analyst Notes

On May 12, 2014, Biogen Idec Inc. (Biogen Idec) announced that Richard A. Rudick, M.D., has joined the Company as Vice President, Development Sciences, Value-Based Medicine. The Company informed that Dr. Rudick will manage Biogen Idec's Value-Based Medicine Group, which will lay emphasis on using latest technology so as to develop inventive programs and tools for better understanding the treatment of multiple sclerosis. According to Biogen Idec, Dr. Rudick is an internationally recognized clinical researcher and has played important roles in several MS clinical trials, including the pivotal clinical trials of Biogen Idec's products, AVONEX® (interferon beta-1a) and TYSABRI® (natalizumab). The full analyst notes on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/2808-BIIB-22May2014.pdf

Questcor Pharmaceuticals, Inc. Analyst Notes

On May 14, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that it has entered into a development collaboration agreement with a privately held European company to develop novel melanocortin peptides. According to the Company, the collaboration comprises of an option to acquire the technology during clinical development. As per Questcor, this transaction will expand its portfolio of melanocortin therapeutics. Steve Cartt, Chief Operating Officer, Questcor, said, "We are particularly excited that this collaboration allows us to build on our success by investing in the development of the next generation of melanocortin therapeutics. Our efforts will focus on novel, receptor-selective peptide compounds designed to target specific melanocortin cellular receptors in order to address specific diseases with high unmet medical need." The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/2808-QCOR-22May2014.pdf

Zimmer Holdings, Inc. Analyst Notes

On May 7, 2014, Zimmer Holdings, Inc. (Zimmer) announced that Persona®, The Personalized Knee System from Zimmer, has been selected as a category finalist for the 2014 Medical Design Excellence Awards (MDEA). Zimmer informed that the Persona Knee System features a number of its exclusive enhancements in orthopaedic technologies, including biologic fixation and long-term stability from its Trabecular Metal™ Technology, and antioxidant protection from its Vivacit-E® Vitamin E Highly Crosslinked Polyethylene bearing surfaces. Stephen E. White, Senior Vice President and GM, Knees, Zimmer, said, "It is an incredible honor to be named a finalist for MDEA. We believe it is recognition of the expertise, effort and energy across the Zimmer Knee team that went into making this product a success for surgeons, institutions and, most importantly, patients." The full analyst notes on Zimmer are available to download free of charge at:

http://www.analystsreview.com/2808-ZMH-22May2014.pdf

Cigna Corporation Analyst Notes

On May 14, 2014, Cigna Corporation (Cigna) announced that Cigna Medical Group (CMG) was honored with the "Daniel T. Cloud Outstanding Practice Award" by The Arizona Partnership for Immunization at the 18th Annual Big Shots for Arizona Awards Ceremony for outstanding immunization levels. Cigna stated that the award is given to medical offices with 90% immunization levels for the children they serve. Andrea Houfek, Senior Medical Director, CMG, quoted, "We are proud to receive the Daniel T. Cloud Outstanding Practice Award for the eleventh year. We are dedicated to making sure the children we care for are protected from vaccine preventable diseases. TAPI's work in the community to educate the public about immunizations is so important, and we are excited to be recognized for such a prestigious award." The full analyst notes on Cigna are available to download free of charge at:

http://www.analystsreview.com/2808-CI-22May2014.pdf

Ctrip.com International Ltd. Analyst Notes

On May 19, 2014, the stock (ADR) of Ctrip.com International Ltd. (Ctrip.com) gained for a fourth consecutive session to close at $53.90, representing a gain of 3.53% over previous day's closing. The Company's stock opened at $52.06 and fluctuated in the range $51.77 - $54.25 during the session. The trading volume for the session was 2.59 million which was more than the previous day's trading volume of 1.59 million. Ctrip.com has gained 18.02% since May 7, 2014 when the Company released its Q1 2014 financial results. The Company had posted an adjusted net income of RMB 1.52 ($0.24) per diluted ADS, compared to RMB 1.87 ($0.30) per diluted ADS, in Q1 2013. On average, analysts polled by Reuters had expected the Company to report adjusted diluted earnings per ADS of $0.11. The full analyst notes on Ctrip.com are available to download free of charge at:

http://www.analystsreview.com/2808-CTRP-22May2014.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review